ArticleBMC infectious diseases2026
Dynamic changes of hand, foot, and mouth disease epidemic crossing three periods in Jiangxi Province, China: a long-term epidemiology retrospective study from 2009 to 2022.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hand, Foot, and Mouth Disease Surveillance in Anhui, After Introduction of the Enterovirus 71 Vaccine and During the COVID-19 Pandemic: Ecological Interrupted Time Series Study.JMIR public health and surveillance · 2026Article
- Clinical and epidemiological characteristics of hospitalized children with enterovirus infection: a retrospective study from 2016 to 2025 at Beijing children's hospital.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHand, foot, and mouth disease (HFMD), a widespread virus-induced infectious disease caused by enteroviruses, imposes a substantial disease burden. This study is to evaluate the impacts of EV-A71 vaccination and COVID-19 non-pharmaceutical interventions (NPI) intensity on HFMD epidemics.
methodA retrospective study was performed based on surveillance data from 2009 to 2022 in Jiangxi Province, China. Joinpoint regression analysis was utilized to analyze long-term trends, wavelet analysis was adopted to explore seasonality and periodicity, spatiotemporal scanning was employed to identify clustering, a generalized linear model (GLM) was used to assess effects of EV-A71 vaccination coverage and NPI intensity on HFMD incidence, and the eXtreme Gradient Boosting (XGBoost) algorithm was employed to develop univariate time-series forecasting models for the incidence of HFMD caused by EV-A71, CVA16, and other EVs.
resultsA marked increase in the annual incidence of HFMD was observed from 2009 to 2016, with a subsequent decrease from 2017 to 2022. Increasing incidence was predominantly detected in the population aged >2 years, especially among those aged 5 to 9 years. The periodicity of HFMD was relatively stable at 12 months and 6 months from 2009 to 2019, but gradually extended to 16 months and 8 months. The proportion of EV-A71 pathogen cases decreased from 28% (Period I) to 0.4% (Period III). The proportion of reported cases aged>2 years demonstrated a chronological upward trend. The model revealed significant independent protection from vaccination and NPI, with the strongest protective effects during autumn and school summer vacation. The forecasts revealed an etiology shift of vaccine-controlled suppression of EV-A71, persistent cyclicality of CVA16, and rising dominance of other EVs.
conclusionThe overall incidence of HFMD declined across three periods, while the incidence in the older child populations increased. A shift in predominant HFMD pathogens was observed and predicted following the rollout of vaccination. Vaccination and NPI interventions are effective in reducing HFMD incidence. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.